Premium
Long‐term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney
Author(s) -
Koga Yuhki,
Matsuzaki Akinobu,
Suminoe Aiko,
Hatano Miho,
Saito Yusuke,
Kinoshita Yoshiaki,
Tajiri Tatsuro,
Taguchi Tomoaki,
Kohashi Kenichi,
Oda Yoshinao,
Tsuneyoshi Masazumi,
Hara Toshiro
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21958
Subject(s) - medicine , peripheral blood , stem cell , transplantation , pathology , peripheral , term (time) , oncology , kidney , kidney transplantation , genetics , physics , quantum mechanics , biology
A 5‐month‐old male with stage II malignant rhabdoid tumor of the kidney (MRTK) and a 24‐month‐old male with stage III MRTK were treated with surgical resection of tumors and chemotherapy of alternating ICE (ifosfamide, carboplatin, and etoposide) and VDC (vincristine, doxorubicin, and cyclophosphamide), followed by high‐dose chemotherapy using etoposide, carboplatin, and melphalan with autologous hematopoietic stem cell transplantation (SCT). Two patients have been alive without any evidence of disease for 30 and 37 months after diagnosis, respectively, and require no medication. Consolidation with SCT should be further studies for selected patients with high‐risk MRTK. Pediatr Blood Cancer 2009;52:888–890. © 2009 Wiley‐Liss, Inc.